Phase I Dose-Escalation Study to Determine the Maximum Tolerated Dose (Mtd) of Nintedanib (Bibf 1120) in Combination with Carboplatin/Pegylated Liposomal Doxorubicin (Pld) in Patients (Pts) with Recurrent Ovarian Cancer (Roc) | Publicación